Seventeen serious adverse events, including two deaths, have been reported in adults aged 62 to 89 following postmarketing use of the Ixchiq chikungunya vaccine. The FDA and CDC have recommended a pause in the use of Ixchiq in patients aged 60 years and older due to serious adverse events, including neurologic and cardiac events. An updated benefit-risk assessment is in progress to evaluate vaccine safety in older patients.

Source: FDA